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1. Introduction  
Inflammatory bowel disease (IBD) is a term used to describe a group of intestinal disorders 
in which inflammation is a major feature. Although rare forms of IBD exist, these diseases 
normally pertain to ulcerative colitis (UC) (Head & Jurenka, 2003) and Crohn’s disease (CD) 
(Baumgart & Sandborn, 2007). There is evidence that these do not represent distinct 
conditions but rather are the same disease with shared etiological factors (Price, 1992); 
however, clinical manifestations (such as the exact location of the pathology or the affected 
individual’s immunological and constitutional endowment) are distinctive between both. 
Despite many years of study, the exact etiology and pathogenesis of these disorders remain 
unclear but great advances have been made using experimental animal models and have 
provided insights into the complex, multi-factorial processes and mechanisms that can 
result in chronic intestinal inflammation (Elson & Weaver, 2003).  
The aim of this chapter is to present an overview of the current expanding knowledge of the 
mechanisms by which lactic acid bacteria and other probiotic microorganisms participate in 
the prevention and treatment of IBD and how genetic engineering techniques can be used to 
improve their effectiveness or create novel therapeutic strains. In the following sections, the 
mechanisms by which these beneficial microorganisms exert their therapeutic effects, which 
include changes in the gut microbiota, stimulation of the host immune responses, 
enhancement of intestinal barrier function and reduction of the oxidative stress due to their 
antioxidant properties will be discussed. 
2. Lactic acid bacteria and inflammatory bowel diseases  
Lactic acid bacteria (LAB) constitute a phylogenetically heterogeneous group of ubiquitous 
microorganisms that are naturally present in high nutrient containing organic products such 
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as foods and occupy a wide range of ecological niches ranging from the surface of plants to 
the gastro-urogenital tract of animals. Currently, the LAB group includes a large number of 
cocci and bacilli, such as species of the genera Carnobacterium, Enterococcus, Lactobacillus, 
Lactococcus, Leuconostoc, Oenococcus, Pediococcus, Streptococcus, Tetragenococcus, Vagococcus 
and Weissella, that normally contain a G+C content inferior to 55% in their chromosomal 
DNA. Although quite diverse, the members of this group have various characteristics in 
common, that include being: (i) Gram-positive; (ii) facultative anaerobes; (iii) non-
sporulating; (iv) non-motile and (v) possess the capacity to convert sugars into lactic acid 
(Nouaille et al., 2003). LAB are one of the most important industrial groups of bacteria that 
are widely used in food production, health improvement and production of 
macromolecules, enzymes and metabolites.  
From a historical point of view, LAB have been used since ancient times in food 
fermentation processes and preservation. Since the 1980’s, many efforts have been made to 
better understand the molecular basis of LAB’s technological properties in order to control 
the industrial processes involving these important microorganisms. Due to their lack of 
pathogenicity, most LAB species have received the GRAS (Generally Recognized As Safe) 
status by the U.S. Food and Drug Administration. In addition to their important 
technological properties in food production (production of lactic acid, decrease of lactose, 
improvement of organoleptic and physical characteristics), various species of LAB, such as 
Lactobacillus casei, Lactobacillus delbrueckii, Lactobacillus acidophilus, Lactobacillus plantarum, 
Lactobacillus fermentum and Lactobacillus reuteri, have been shown to possess therapeutic 
properties since they are able to prevent the development of some diseases as shown mostly 
using animal models and have the capacity to promote beneficial effects in human and 
animal health (LeBlanc et al., 2008). Because of all of their documented beneficial effects, 
certain strains of LAB have been designated as being probiotic that have been defined by the 
FAO/WHO as “live microorganisms which when administered in adequate amounts confer a health 
benefit on the host” (FAO/WHO, 2001). Some of the health benefits which have been claimed 
for probiotics include: improvement of the normal microbiota, prevention of infectious 
diseases and food allergies, reduction of serum cholesterol, anticarcinogenic activity, 
stabilization of the gut mucosal barrier, immune adjuvant properties, alleviation of intestinal 
bowel disease symptoms, and improvement of the digestion of lactose in intolerant hosts 
(Galdeano et al., 2007). The most commonly used strains as probiotics are members of 
lactobacilli, enterococci and bifidobacteria groups (Ouwehand et al., 2002). Currently, many 
products containing probiotics are available on retail shelves throughout the world because 
of the increase consumer demand for healthier natural foods that can increase their overall 
well-being (Galdeano et al., 2007). The specific health effects of selected probiotic strains 
have been confirmed by well documented double blind controlled human clinical trials and 
are becoming increasingly accepted. However, many proposed beneficial effects of 
probiotics still need further research and more information about their mechanisms of action 
is needed in order to confirm that they can be useful in the prevention and treatment of 
other specific diseases (Ouwehand et al., 2002). 
2.1 Mechanisms of action of LAB against IBD 
It has been shown that LAB and other probiotic microorganims can counteract 
inflammatory processes in the gut by stabilizing the microbial environment and the 
permeability of the intestinal barrier, and by enhancing the degradation of enteral antigens 
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and altering their immunogenicity (Isolauri et al., 2004). Some of these disease preventing 
effects have been recently reviewed (del Carmen et al., 2011); however, a few examples of 
each of the mechanisms by which LAB exert anti-IBD effects will be given to demonstrate 
their potential uses. 
2.1.1 Modulation of the gut microbiota 
The first mechanism that LAB use to prevent IBD is the modulation of the gastrointestinal 
microbiota of animals. It was reported that Lactobacillus (L.) reuteri could be used to prevent 
colitis in IL-10 knock-out (KO) mice by increasing the number of LAB in the gastrointestinal 
tract (Madsen et al., 1999). Neonatal mice presented a decreased concentration of colonic 
Lactobacillus species and an increased concentration of mucosal adherent bacteria. Oral 
administration of the prebiotic lactulose increased the levels of Lactobacillus species and 
rectal swabbing with L. reuteri restored Lactobacillus levels to normal and reduced the 
number of adherent bacteria within the colon. These effects were associated with the 
attenuation of UC (Madsen et al., 1999). In a placebo-controlled trial, orally administered L. 
salivarius UCC118 reduced prevalence of colon cancer and mucosal inflammatory activity in 
IL-10 KO mice by modifying the intestinal microbiota in these animals: Clostridim (C.) 
perfringens, coliforms, and enterococcus levels were significantly reduced in the probiotic fed 
group (O’Mahony et al., 2001). 
Gut microbiota can antagonize pathogenic bacteria by conferring a physiologically 
restrictive environment inhibiting bacterial adherence and translocation. Probiotic bacteria 
also decrease luminal pH, as has been demonstrated in patients with UC following ingestion 
of the probiotic preparation VSL#3, a mixture of 4 lactobacilli strains (L. plantarum, L. casei, 
L. acidophilus, and L. delbrueckii ssp. bulgaricus), 3 bifidobacteria strains (Bifidobacterium (B.) 
infantis, B. breve, and B. longum), and 1 strain of Streptococcus (S.) salivarius ssp. thermophilus 
(Venturi et al., 1999). 
Another mechanism by which probiotics can exert a positive effect by inhibiting pathogenic 
microorganisms is by producing antimicrobial substances such as bacteriocins. Several 
bacteriocins produced by different Lactobacillus species have been described (Klaenhammer, 
1988). The inhibitory activity of these bacteriocins varies; for example, the probiotic L. 
salivarius UCC118 produces a peptide that inhibits a broad range of pathogens such as 
Bacillus, Staphylococcus, Enterococcus, Listeria, and Salmonella species (Flynn et al., 2002). 
Lacticin 3147, a broad-spectrum bacteriocin produced by a Lactococcus (Lc.) lactis strain, 
inhibits a range of genetically distinct C. difficile isolated from healthy subjects, patients with 
IBD and from different origins (Rea et al., 2007). 
The Symbiotic Instant Mixture (SIM) containing a prebiotic compound inulin, and a 
combination of probiotic microorganisms (L. acidophilus La-5 and B. lactis Bb-12) 
significantly reduced inflammation in transgenic rats that produce human HLA-B27–┚2-
microglobulin. The effect was enhanced by combination with metronidazole, suggesting a 
synergistic effect of the combination of antibiotics and probiotics in the treatment of 
experimental colitis (Schultz et al., 2004). In a double-blind randomized study, the efficacy of 
VSL#3 combined with antibiotic treatment on the post-operative recurrence of CD was 
compared with treatment with mesalazine alone. Combination of antibiotic and probiotic 
treatment was more efficient in prophylaxis of post-operative recurrence of Crohn's disease 
(Campieri et al., 2000). 
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2.1.2 Modulation of the host immune responses and enhancement of intestinal barrier 
function 
The intestinal mucosa is the body’s first line of defense against pathogenic and toxic 
invasions from food. After ingestion, orally administered antigens encounter the GALT (Gut 
Associated Lymphoid Tissue), which is a well-organized immune network that protects the 
host from pathogens and prevents ingested proteins from hyperstimulating the immune 
response through a mechanism called oral tolerance (Weiner et al., 1997).  
The main mechanism of protection given by the GALT is humoral immune response 
mediated by secretory IgA (s-IgA) which prevents the entry of potentially harmful antigens, 
while also interacting with mucosal pathogens without potentiating damage. The 
stimulation of this immune response could thus be used to prevent certain infectious 
diseases that enter the host through the oral route. An increasing number of probiotic strains 
have shown to highly increase s-IgA,  therefore the stimulation of IgA-producing cells is 
often considered a must in probiotic screening trials (O'Sullivan, 2001). 
Numerous studies have shown that certain strains of lactobacilli and bifidobacteria can 
modulate the production of cytokines (mediators produced by immune cells) that are 
involved in the regulation, activation, growth, and differentiation of immune cells and have 
been recently reviewed (de Moreno de LeBlanc et al., 2011). These probiotic microorganisms 
are able to prevent and treat certain inflammatory diseases in the gastrointestinal tract 
through the repression of pro-inflammatory cytokines. In this sense, the anti-inflammatory 
effect of yoghurt administration to mice was studied using a TNBS induced acute intestinal 
inflammation model. The animals that received yoghurt continuously (before and after 
TNBS) had lower intestinal damages and improved anti-inflammatory response in the gut 
(de Moreno de LeBlanc et al., 2009). This improvement of the immune response was related 
with beneficial changes in the intestinal microbiota and differences in the cytokine 
production and secretion with increases of IL-10 and decreases of IL-17 in the mice given 
yoghurt. The same yoghurt was analyzed in a mouse model of recurrent inflammation 
where the administration of the fermented product after the acute episode, when the 
animals were recovered, prevented the recurrence of the inflammation (Chaves et al., 2011). 
One of the central transcription factors mediating inflammatory responses is the nuclear 
factor B (NF-B). NF-B is required for the transcriptional activation of a number of 
inflammatory effectors, including IL-8, TNF-┙, IL-6, Cox2, iNOS and many others and, its 
deregulation has been detected in many inflammatory conditions. It was shown that a 
number of LABs can suppress inflammatory signals mediated by NF-B. These include 
strains of the phylogenetically closely related species L. acidophilus and L. johnsonii, which 
have been isolated from the human GI tract and form part of the acidophilus complex.  
One of the ways by which probiotics can exert immunomodulatory activities is by 
increasing IL-10 production that can in turn help in preventing certain IBD that are caused 
by abnormal inflammatory responses (de Moreno de LeBlanc et al., 2011). However, not all 
probiotic strains act in the same manner. Anti-inflammatory effects, such as stimulation of 
IL-10 producing cells, are strain dependent traits, and their effectiveness also depends on 
the concentrations used and the method of administration. By increasing IL-10 levels and in 
consequence decreasing inflammatory cytokines such as TNF-┙, IFN-┛, and IL-17 some LAB 
can prevent the appearance of local inflammatory diseases and could be used as an adjunct 
therapy with conventional treatments (de Moreno de LeBlanc et al., 2011). 
Enhancement of intestinal barrier function is another mechanism by which probiotic 
bacteria may benefit the host. The exact mechanisms by which probiotic bacteria enhance 
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gut mucosal barrier function are unclear, but may relate to alterations in mucus or chloride 
secretion or changes in mucosal cell-cell interactions and celular stability through 
modulation of cytoeskeletal and tight junction protein phosphorilation (Hilsden et al., 1996, 
Madsen et al., 2001, Meddings, 2008, Ng et al., 2009, Schmitz et al., 1999). 
Oral treatment with VSL#3 normalized colonic physiologic function and barrier integrity in 
IL-10 KO mice as assessed by short circuit currents, transepithelial potential differences, and 
mannitol fluxes in excised tissues from mice (Madsen et al., 2001). 
L. plantarum and L. reuteri enhanced barrier function on a methotrexate-induced enterocolitis 
rat model (Mao et al., 1996); and colonization of healthy mice intestinal loops with L. brevis 
reduced intestinal permeability (Garcia-Lafuente et al., 2001). 
Some probiotic bacteria modify MUC gene expression and mucus secretion. For example, L. 
plantarum 299v induced intestinal mucin gene (MUC2 and MUC3) expression in vitro (Mack 
et al., 1999). VSL#3 also induced expression of mucins in vitro and increased transepithelial 
resistance (TER), prevented pathogen-induced decrease in TER, and stabilized tight 
junctions. In this way, probiotics and protein(s) released by these organisms may 
functionally modulate the intestinal epithelium of the host by different mechanisms, 
including the competition of whole organisms for contact with the epithelial surface as well 
as stabilization of the cytoskeleton and barrier function and the induction of mucin 
expression (Otte & Podolsky, 2004). 
2.1.3 Reduction of the oxidative stress 
As a result of recurrent and abnormal inflammation, IBD appears to be associated with 
oxidative stress, which is characterized by an uncontrolled increase in reactive oxygen 
species (ROS) concentrations in the gastrointestinal tract. Several studies have established a 
correlation between the increase in ROS production and disease activity in inflamed 
biopsies of IBD patients. Therefore, a suggested mechanism by which LAB could prevent 
inflammation is through the expression of antioxidant enzymes that are able to decrease 
ROS levels or at least impair their formation. 
ROS are normal byproducts of oxygen metabolism (such as superoxide ions, free radicals 
and peroxides). These small molecules can be generated in aerobiosis by flavoproteins and 
by phagocytes during inflammatory reactions. At low concentrations, ROS participate in cell 
signaling and regulatory pathways. However, when present in large amounts, they act to 
eliminate infectious agents by causing significant damages to cell structures and 
macromolecular constituents such as DNA, RNA, proteins and lipids. When ROS 
concentration exceeds the capacity of cell defense systems, toxicity is triggered. It is well 
known that oxidative damage occurs during the pathogenesis of cancer, cirrhosis, 
atherosclerosis and other chronic diseases. It has been shown for example that human tumor 
cells produce and excrete large amounts of H2O2 that might participate in tumor invasion 
and proliferation (Szatrowski & Nathan, 1991). Thus, oxidative stress plays an important 
role in pathologies of the gastrointestinal tract of humans such as IBD as well as in certain 
types of cancers. 
In order to offset oxidative stress, aerobic cells like those of the normal intestinal mucosa are 
equipped with a complex antioxidant defense system which includes enzymatic and non-
enzymatic components having synergistic and interdependent effects on each other. The 
normal intestinal mucosa is equipped with a network of antioxidant enzymes such as 
catalase (Cat), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione-s-
transferase (GST), and superoxide dismutase (SOD) that are able to neutralize ROS. The 
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activities of these enzymes are usually balanced to maintain a low and continual steady-
state level of ROS; however, the levels of these enzymes are frequently depleted in IBD 
patients (Kruidenier et al., 2003). Probiotic LAB strains expressing high levels of antioxidant 
enzymes could increase these enzymatic activities in specific locations of the gastrointestinal 
tract and could thus contribute to prevent oxidative epithelial damages, giving rise to 
potential applications for IBD treatment or post-cancer drug treatments. Since few 
microorganisms produce antioxidant enzymes at the required concentrations to exert 
biological effects, genetic engineering strategies have been employed to produce antioxidant 
producing LAB, these will be discussed in another section of this chapter. 
Superoxide dismutase (SOD) is considered as the first line of defense against ROS and is a 
member of the family of metalloenzymes that catalyze the oxido-reduction of superoxide 
anion to H2O2. There are three different forms of this enzyme according to their metal 
center: manganese, copper-zinc, or iron. These enzymes are found across a broad range of 
organisms, which can use one, two, or all three enzymes to meet their antioxidant needs. In 
most Streptococcus and Lactococcus spp., elimination of ROS is accomplished through the 
action of Mn-SOD (Sanders et al., 1995). It has also been reported that two strains of L. 
fermentum, named E-3 and E-18, and a strain of S. thermophilus showed significant 
antioxidative activity due to production of Mn-SOD (Kullisaar et al., 2002). Furthermore, 
recent experimental data indicate that subcutaneous treatment with SOD significantly 
reduces peroxidation reactions in the inflamed colon and confers significant amelioration of 
colonic inflammatory changes in a rat model of TNBS colitis (Segui et al., 2004). In addition, 
treatment with SOD decreases oxidative stress and adhesion molecule upregulation in 
response to abdominal irradiation in mice. 
Catalase is another major antioxidant enzyme that catalyzes the decomposition of hydrogen 
peroxide into water and oxygen. Catalases are widespread in aerobic (facultative or not) 
bacteria such as E. coli and Bacillus (B.) subtilis (Rochat et al., 2005). There are two different 
classes of catalases according to their active-site composition: one is heme-dependent and 
the other, also named pseudocatalase is manganese-dependent. By definition, LAB are 
catalase negative microorganisms, thus genetic modifications are necessary in order for 
them to produce this important antioxidant enzyme. 
3. Genetics of LAB and recombinant protein production strategies 
Comparative genomics has facilitated our understanding of LAB evolution and has 
indicated that a combination of gene gain and loss occurred during the evolution of these 
bacteria in various environmental habitats (Makarova et al., 2006). Beginning with the 
genome sequencing of Lc. lactis IL-1403 in 1999 (Bolotin et al., 1999), by July 2011 there were 
314 LAB genomes (98 complete and 216 in progress) publicly available at the National 
Center for Biotechnology Information (NCBI, 2011).  
Lc. lactis is widely used in the dairy industry and is normally used as the model for other 
LAB, not only because of its economic importance, but also because of the following 
features: (1) it has a completely sequenced genome; (2) it is genetically easy to manipulate; 
and (3) many genetic tools have already been developed for this species. 
Studies based on the identification and isolation of wild-type plasmids from L. lactis and 
other LAB have made it possible to develop various cloning vectors. Using molecular 
biology techniques, these plasmids have been manipulated so that they have become 
important tools for cloning and studying genes of interest, both those of prokaryotes and 
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eukaryotes. They basically consist of (1) origin of replication (ori), (2) selection marker (gene) 
for antibiotic resistance, and (3) multiple-cloning site. 
The expression of heterologous proteins in Lc. lactis has been favored both by advances in 
genetic knowledge and by new developments in molecular biology techniques. Using this 
duet of tools to obtain increased levels of these proteins and control their production, 
various vectors containing constitutive or inductive promoters were developed and 
currently constitute the basis of all expression systems in Lc. lactis and other LAB. 
3.1 LAB expression systems 
LAB are potential candidates to be used as vehicles for the production and delivery of 
heterologous proteins of vaccinal, medical, or technological interest and various delivery 
systems are now available for these probiotic microorganisms (Miyoshi et al., 2010). 
Different genetic engineering strategies in LAB have been used to: improve their 
carbohydrate fermenting properties (lactose, galactose), increase specific metabolite 
production (diaceyl, acetoin), produce or increase enzymatic activities (proteolytic enzymes, 
┙- and ┚-galactosidase, ┙-amylase), or conferring them the capacity to produce beneficial 
compounds such as bacteriocins, exopolysaccharide (EPS) and other sugars, vitamins, 
antioxidant enzymes and anti-inflammatory cytokines (Sybesma et al., 2006). 
A series of studies to develop new strains and efficient expression systems has been 
conducted to use LAB as “cell factories” for the production of proteins (Djordjevic & 
Klaenhammer, 1998). However, in order for some of these proteins (enzymes and antigens) 
produced by bacteria to attain the desired biological activity levels, it is necessary that they 
correctly target specific cellular locations: (1) cytoplasm, (2) membrane, or (3) extracellular 
environment. 
3.1.1 Nisin-Controlled Expression (NICE) system 
A versatile and tightly controlled gene expression system was first described in 1995, based 
on the auto-regulation mechanism of the bacteriocin nisin, denominated the Nisin-
Controlled Expression (NICE) system (Kuipers et al., 1995). This system has become one of 
the most successful and widely used tools for regulated gene expression in Gram-positive 
bacteria. An extensive overview of the different applications in lactococci and other Gram-
positive bacteria has been published 10 years after the NICE system was first published  
(Mierau & Kleerebezem, 2005) showing its potential use in: (1) over-expression of 
homologous and heterologous genes for functional studies and to obtain large quantities of 
specific gene products, (2) metabolic engineering, (3) expression of prokaryotic and 
eukaryotic membrane proteins, (4) protein secretion and anchoring in the cell envelope, (5) 
expression of genes with toxic products and analysis of essential genes and (6) large scale 
applications. 
3.1.2 Xylose-Inducible Expression System (XIES) 
Another controlled production system to target heterologous proteins to cytoplasm or 
extracellular medium was described for Lc. lactis NCDO2118 based on the use of a xylose-
inducible lactococcal promoter, PxylT (Miyoshi et al., 2004). The capacities of the Xylose-
Inducible Expression System (XIES) to produce cytoplasmic and secreted proteins were 
tested using the Staphylococcus aureus nuclease gene (nuc) fused or not to the lactococcal 
Usp45 signal peptide. Xylose-inducible gene expression is tightly controlled and resulted in 
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high-level and long-term protein production, and correct targeting either to the cytoplasm 
or to the extracellular medium. Furthermore, this expression system is versatile and can be 
switched on or off easily by adding either xylose or glucose, respectively, and has potential 
as an alternative and useful tool for the production of proteins of interest in Lc. lactis. 
3.1.3 pValac 
A new plasmid vector for DNA delivery using lactococci, the pValac plasmid was 
constructed by the fusion of: i) an eukaryotic region, allowing the cloning of an antigen of 
interest under the control of the pCMV eukaryotic promoter to be expressed by a host cell 
and ii) a prokaryotic region allowing replication and selection of bacteria (Guimaraes et al., 
2009). In order to evaluate pValac functionality, the gfp ORF was cloned into pValac 
(pValac:gfp) and was analyzed by transfection in PK15 cells. Invasiveness assays of Lc. lactis 
inlA+ strains harbouring pValac:gfp into Caco-2 cells demonstrated the potential of pValac 
to deliver DNA and trigger DNA expression by epithelial cells.  
4. Prevention of IBD using genetically modified LAB 
As described above, LAB are potential candidates to be used as vehicles for the production 
and delivery of heterologous proteins of vaccinal, medical, or technological interest and 
various delivery systems are now available for these probiotic microorganisms (Miyoshi et 
al., 2010). The use of LAB that produce anti-inflammatory compounds (such as IL-10 and 
antioxidant enzymes) in the treatment of colitis and IBD will be discussed in the following 
sections. 
4.1 Antioxidant enzyme producing strains 
As stated earlier, in IBD patients, oxidative stress occurs as a result of recurrent and 
abnormal inflammation with an associated increase in ROS concentrations. 
Since few microorganisms produce antioxidant enzymes at concentrations required to exert 
biological effects, genetic engineering strategies have been employed to produce antioxidant 
producing LAB. Recent reviews have shown the potential uses of such strains in the 
treatment of IBD using a variety of animal models (Spyropoulos et al., 2010). LAB have been 
used to locally deliver antioxidant enzymes (such as SOD) directly to the intestines, an 
important breakthrough since oral administration of SOD is greatly limited by its short 
lifespan (5-10 min) in the hostile conditions of the gastrointestinal tract. It has been shown 
that genetically engineered L. plantarum and Lc. lactis capable of producing and releasing 
SOD exhibit anti-inflammatory effects in a TNBS colitis model (Han et al., 2006). Another 
experimental study demonstrated that L. gasseri producing manganese SOD had significant 
anti-inflammatory activity reducing the severity of colitis in IL-10-deficient mice (Carroll et 
al., 2007). Recent data has shown that SOD producing L. casei BL23 was able to significantly 
attenuate the TNBS-induced damages as shown by higher survival rates, decreased animal 
weight loss, lower bacterial translocation to the liver and the prevention of damage to the 
large intestines (LeBlanc et al., 2011). This is in agreement with previous results that have 
shown that the same SOD-expressing strain of L. casei was able to slightly attenuate the 
colonic histological damage score of a DSS-induced colitis model (Watterlot et al., 2010). 
Since Lc. lactis has no catalase (as is also the case for the majority of LAB), the B. subtilis 
heme catalase Kat E gene was introduced into this industrially important microorganism 
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giving rise to a strain capable of producing active catalase that can provide efficient 
antioxidant activity (Rochat et al., 2005). Recently, the heterologous expression of non-heme 
catalase in bacteria relevant to dairy industries (L. casei) has also been reported (Rochat et al., 
2006). This latter strain offers the advantage that no exogenous heme has to be added to the 
culture medium in order to exert an efficient catalase activity. We have previously shown 
that the catalase-producing Lc. lactis strain was able to prevent tumor appearance in the 
colon (de Moreno de LeBlanc et al., 2008). In another study, we have shown that a catalase 
producing strain of L. casei BL23 significantly decreased the physiological damages caused 
by the TNBS administration (LeBlanc et al., 2011). This result is similar to those obtained 
previously where it was shown that both the native strain of L. casei BL23 and its catalase 
producing derivative presented a significant reduction of caecal and colonic inflammatory 
scores (Rochat et al., 2007). 
4.2 IL-10 producing strains 
Genetically modified Lc. lactis secreting IL-10 provides a novel therapeutic approach for 
IBD. The first description of Lc. lactis that can secrete biologically active IL-10 was published 
in 2000 (Schotte et al., 2000). In this pioneer study, murine- IL-10 was synthesized as a fusion 
protein, consisting of the mature part of the eukaryotic protein fused to the secretion signal 
of the lactococcal Usp45 protein. Intragastric administration of this recombinant Lc. lactis 
strain prevented the onset of colitis in IL-10 KO mice and caused a 50% reduction of the 
inflammation in DSS -induced chronic colitis (Steidler et al., 2000). 
The application of IL-10 producing LAB is not only limited to the treatment of IBD. It was 
recently shown that treatment of asthma with a Lc. lactis expressing murine IL-10 was 
efficient since this LAB modulated experimental airway inflammation in the mouse model 
(Marinho et al., 2010). Lc. lactis producing recombinant IL-10 used in this study was efficient 
in suppressing lung inflammation, independently of Treg cells, since this cytokine plays a 
central role in the regulation of inflammatory cascades, allergen-induced airway 
inflammation and non-specific airway responsiveness (Tournoy et al., 2000). In another 
study, it was shown that oral administration of an IL-10-secreting Lc. lactis strain could 
prevent food-induced IgE sensitization in a mouse model of food allergy (Frossard et al., 
2007). These studies confirm that IL-10 secreting LAB hold potential for the treatment of 
many inflammatory diseases where this cytokine acts as a modulating compound. 
Although a clear positive effect of these recombinant strains has been demonstrated, the 
exact mechanism by which the beneficial effect of the IL-10-producing Lc. lactis on the 
mucosa is produced remains unclear. A recent study has demonstrated the uptake of IL-10-
secreting Lc. lactis by the paracellular route in inflamed mucosal tissue in mouse models of 
chronic colitis, suggesting that IL-10 production by these LAB residing inside the mucosa in 
the vicinity of responsive cells can improve the local action of IL-10 in inflamed tissue and 
the efficiency of the treatment (Waeytens et al., 2008). In another study, it was shown that 
genetically engineered Lc. lactis secreting murine IL-10 could modulate the functions of bone 
marrow-derived DC in the presence of LPS (Loos et al., 2009). This data suggest that the 
beneficial effects of IL-10 secreting LAB during chronic colitis might involve inhibition of 
CD4+ Th17 cells and a reduced accumulation of these cells as well as other immune cells at 
the site of inflammation. 
In another study, we have evaluate the anti-inflammatory effect of the administration of 
milks fermented by Lc. lactis strains that produce IL-10 under the control of the XIES, using a 
Trinitrobenzenesulfonic acid induced colitis murine model. Mice that received milks 
www.intechopen.com
 
Current Concepts in Colonic Disorders 
 
232 
fermented by Lc. lactis strains producing IL-10 in the cytoplasm (Cyt strain) or secreted to 
the product (Sec strain) showed lower damage scores in their large intestines, decreased 
IFN-┛ levels in their intestinal fluids and lower microbial translocation to liver, compared to 
mice receiving milk fermented by the wild-type (Wt) strain or those not receiving any 
treatment (unpublished data). The results obtained in this study show that the employment 
of fermented milks as a new form of administration of IL-10 producing L. lactis is effective in 
the prevention of IBD in a murine model. This new approach could lead to the development 
of novel fermented products with therapeutical purposes; suitable for specific populations 
suffering from gastrointestinal disorders or prone to acquiring them. Similar strains could 
also be included in probiotic mixtures together with other strains that are able to prevent 
inflammation by other mechanisms such as immune stimulation or that possess antioxidant 
properties. 
5. Prospective uses of GM-LAB 
Although there is no scientific evidence that supports the notion that genetically modified 
(GM) foods or microorganisms are dangerous for human consumption, it is necessary to 
demonstrate that these are innocuous in order to alleviate the fears held by the general 
public associated with the use of genetically modified organisms, if we want to use designer 
probiotics to extend the range of applications covered by natural probiotics. Also, the proper 
design of GM-LAB is essential in order to eliminate the risks of dissipation in the 
environment and prevent the transfer of certain genes (such as antibiotic resistance genes) to 
other microorganisms. 
The construction of a biological containment system for a genetically modified Lc. lactis for 
intestinal delivery of human IL-10 is an important step forward for the safe use of GM-LAB 
for human therapeutic purposes (Steidler et al., 2003). In this study, the thymidylate 
synthase gene of Lc. lactis was replaced by the human IL-10 gene, making this strain 
incapable of growing when deprived of thymidine or thymine. This strain does not contain 
any antibiotic resistance markers and because of its thymidine auxotrophy, it cannot 
disseminate in the environment making it one of the safest GM strains ever engineered. This 
containment system was recently evaluated in CD patients and it was shown that no 
adverse effects were produced after consuming this GM-LAB and that it could only be 
recovered in feces when thymidine was added (Braat et al., 2006). Although only 
preliminary results from this phase 1 trial were obtained, the use of genetically modified 
bacteria for mucosal delivery of proteins is a feasible strategy in human with chronic 
intestinal inflammation (Braat et al., 2006). 
Intragastric administration of Lc. lactis genetically modified to secrete IL-10 in situ in the 
intestine was shown to be effective in healing and preventing chronic colitis in mice. 
However, its use in humans is hindered by the sensitivity of Lc. lactis to freeze-drying and 
its poor survival in the gastrointestinal tract, reasons for which novel means for more 
effective mucosal delivery of therapeutic LAB are currently being developed (Huyghebaert 
et al., 2005a, b, Termont et al., 2006). 
6. Conclusion 
This review has shown that probiotics have been extensively used in order to prevent and 
treat inflammatory bowel diseases. The mechanism of action of these beneficial 
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microorganisms, which includes changes in the gut microbiota, stimulation of the host 
immune responses, enhancement of intestinal barrier function and reduction of the 
oxidative stress due to their antioxidant properties and antioxidant enzyme production has 
been demonstrated principally using animal models and in specific human trials. It has 
recently been suggested that there is a lack of well-designed, large, randomized, placebo-
controlled trials that can certify that probiotics are effective in the prevention and treatment 
of IBD (Mallon et al., 2007). Additional studies such as the double-blind, randomized, 
placebo-controlled clinical trial of the treatment of relapsing mild-to-moderate ulcerative 
colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment (Tursi 
et al., 2010) are required to confirm animal data and are necessary to convince the medical 
and general community of the benefits and potential application of probiotics in the 
prevention and treatment of IBD. 
Although probiotic effects are a strain dependent trait, using modern genetic engineering 
techniques it is theoretically possible to obtain strains that can exert a variety of beneficial 
properties. For example, the introduction of antioxidant enzyme genes or cytokine 
producing capabilities in current probiotic strains that have natural anti-inflammatory 
properties, such as the ability to modulate the immune dependant anti-inflammatory 
processes, could generate very useful strains that could be applied in the treatment of a 
variety of inflammatory diseases. These strains could also be included in treatment 
protocols since it has been shown that probiotics can enhance the effectiveness of traditional 
IBD treatments. However, before proposing the genetic modification of anti-inflammatory 
strains, the innate mechanisms of the potential host strains should be demonstrated in 
properly designed large scale human clinical trials. These trials are essential in future 
studies using the engineered strains to demonstrate the differences between the native and 
modified microorganisms. 
The consumption of engineered strains by humans is still highly controversial due to the 
public perception that genetic manipulation is not “natural”. Scientists must perform well-
designed studies where the results are divulged to the general populations in order to 
inform consumers of the obvious beneficial effects these novel techniques can confer with 
the minimum of risk to their health and to the environment. Throughout the course of 
history, most novel treatments have met resistance from potential benefactors, it is thus 
important to show that the potential benefits are highly superior than the risks for novel 
treatments to be completely accepted by the population as a whole. 
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The 21st Century has seen a resurgence of research of the gastrointestinal tract, especially since it was
established that it plays a central role as an immune system organ and consequentially has a huge impact on
causation, impact and transmission of most human ailments. New diseases such as the Acquired
Immunodeficiency Syndrome, hepatitis and tumours of the gastrointestinal tract have emerged and they are
currently subjects of intensive research and topics of scientific papers published worldwide. Old diseases like
diarrhea have become extremely complex to diagnose with new and old pathogens, drugs, tumours and
malabsorptive disorders accounting for the confusion. This book has set out algorithms on how to approach
such conditions in a systematic way both to reach a diagnosis and to make patient management cheaper and
more efficient. "Current Concepts in Colonic Disorders" attempts to put all the new information into proper
perspective with emphasis on aetiopathogenesis and providing rational approach to management of various
old and new diseases. As the book editor, I have found this first edition extremely interesting and easy to
understand. Comments on how to improve the content and manner of presentation for future editions are
extremely welcome.
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